Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ASO Visual Abstract: Comparing Resident Team Performance in Complex Surgical Oncology: A Single-Institution Cohort Study.

Annals of surgical oncology·2026

Same author

Comparing Resident Team Performance in Complex Surgical Oncology: A Single-Institution Cohort Study.

Annals of surgical oncology·2026

Same author

Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells.

Cancer immunology research·2026

Same author

Patient selection, practice patterns, and perioperative outcomes for robotic splenectomy: a contemporary ACS-NSQIP analysis.

Surgical endoscopy·2026

Same author

Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterations.

Cell reports·2026

Same author

Marital Status Is Associated With Treatment Attainment in Pancreatic Adenocarcinoma.

Journal of surgical oncology·2026

Search research articles

Related Experiment Video

Updated: Jul 4, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Neoadjuvant therapy for resectable melanoma.

Cimarron E Sharon¹, Giorgos C Karakousis²

¹Department of Surgery, Division of Endocrine and Oncologic Surgery, Hospital of the University of Pennsylvania, Maloney 4 3400 Spruce Street, Philadelphia, PA, 19104, USA. cimarron.sharon@pennmedicine.upenn.edu.

Clinical & Experimental Metastasis

|January 28, 2024

Summary

This summary is machine-generated.

Neoadjuvant therapy for stage III/IV melanoma shows improved patient response and reduced toxicity compared to adjuvant therapy alone. Further research will personalize treatment plans based on patient response to neoadjuvant therapy.

Keywords:

Immune therapy Melanoma Neoadjuvant therapy

More Related Videos

A Melanoma Patient-Derived Xenograft Model

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Related Experiment Videos

Last Updated: Jul 4, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

A Melanoma Patient-Derived Xenograft Model

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Area of Science:

Oncology
Dermatology
Clinical Trials

Background:

Standard care for resectable stage III/IV melanoma involves surgery followed by adjuvant therapy.
Recent advancements have introduced systemic therapies for neoadjuvant use in melanoma patients.

Purpose of the Study:

To review clinical trials on neoadjuvant therapy for resectable stage III/IV melanoma.
To identify optimal neoadjuvant treatment regimens for maximizing patient response and minimizing toxicity.

Main Methods:

Systematic review of clinical trials investigating neoadjuvant therapy in melanoma.
Analysis of treatment outcomes, patient response rates, and toxicity profiles.

Main Results:

Neoadjuvant therapy demonstrates advantages over adjuvant therapy alone for resectable stage III/IV melanoma.
Identified optimal regimens enhance patient response and reduce treatment-related toxicities.

Conclusions:

Neoadjuvant therapy is a promising approach for managing resectable stage III/IV melanoma.
Future research should focus on using response to neoadjuvant treatment for prognostication and personalized treatment planning.